Testosterone Enanthate Dosing for Adults (30, 49)

Who Qualifies for TRT at Ages 30 to 49

A diagnosis of male hypogonadism requires two morning total testosterone values below 300 ng/dL paired with at least one clinical symptom: fatigue, reduced libido, erectile dysfunction, or loss of lean mass. The Endocrine Society 2018 guidelines specify that testing should occur between 7:00 and 10:00 AM, when diurnal testosterone peaks. Repeat confirmation is mandatory because single readings misclassify roughly 30% of men due to biological variability [1].

Men in this age bracket often present after noticing sexual symptoms first. A 2020 cross-sectional analysis of the NHANES dataset estimated that 10 to 12% of U.S. men aged 30 to 49 have total testosterone below 300 ng/dL, though only a fraction carry symptomatic hypogonadism [2]. Before starting testosterone enanthate, clinicians should rule out reversible causes: obstructive sleep apnea, opioid use, hyperprolactinemia, and obesity-driven suppression of the hypothalamic-pituitary-gonadal axis.

A complete baseline panel includes total and free testosterone, LH, FSH, prolactin, CBC, lipid panel, PSA, hepatic function, and a metabolic panel. The American Urological Association (AUA) 2018 guideline also recommends a baseline hematocrit, because testosterone stimulates erythropoiesis and men with elevated baseline values carry higher polycythemia risk [3].

Standard Starting Dose and Frequency

The FDA-approved prescribing information for testosterone enanthate lists a range of 50 to 400 mg administered intramuscularly every two to four weeks [4]. In clinical practice, most prescribers have moved toward weekly dosing. The reason is pharmacokinetic: testosterone enanthate has a half-life of roughly 4.5 days, so biweekly injections produce a pronounced peak-to-trough swing that many patients feel as an energy crash in the second week [5].

A starting protocol of 100 mg IM once weekly keeps serum levels within a tighter physiologic band. Some clinicians begin at 75 mg weekly for smaller-framed men or those with borderline hematocrit values (above 50%). The Endocrine Society guideline explicitly notes that dose individualization, not a fixed regimen, produces the best clinical outcomes [1].

For men who prefer less frequent injections, 200 mg every 14 days remains acceptable. The tradeoff is a wider hormonal fluctuation. Peak values may exceed 1 to 100 ng/dL at 48 to 72 hours post-injection, while trough values can dip below 300 ng/dL by day 12 to 14. Patients who report mood instability or fatigue late in the cycle are candidates for splitting the dose into weekly administration.

How to Titrate: The 6-Week Lab Check

Draw trough labs 6 to 8 weeks after starting or changing a dose. "Trough" means the morning of (or the day before) the next scheduled injection. The primary target is a total testosterone of 450 to 600 ng/dL at trough, which places the patient in the mid-normal reference range without supraphysiologic peaks [1].

If the trough value is below 400 ng/dL and symptoms persist, increase the dose by 25 mg per week. If trough testosterone exceeds 700 ng/dL or hematocrit rises above 54%, reduce by 25 mg per week. These 25 mg increments may seem small, but they shift steady-state trough levels by approximately 80 to 120 ng/dL in most patients [6].

Free testosterone and sex hormone-binding globulin (SHBG) add context. A man with a total testosterone of 500 ng/dL but an SHBG of 60 nmol/L may have a calculated free testosterone below the reference range, warranting a modest dose increase. Conversely, low SHBG (common in obesity and insulin resistance) can inflate free testosterone relative to total, making a "normal" total level adequate.

Once stable, the Endocrine Society recommends labs every 6 to 12 months: total testosterone, hematocrit, and PSA. A 2010 meta-analysis in The Lancet of 51 randomized trials (N = 3,422) found that testosterone therapy increased hemoglobin by an average of 0.8 g/dL across formulations, reinforcing the need for serial hematocrit monitoring [7].

Injection Technique and Site Rotation

Testosterone enanthate is formulated in sesame or cottonseed oil for deep intramuscular injection. Standard needle gauge for IM delivery is 22 to 25 gauge, 1 to 1.5 inches, depending on body composition. The three recommended sites are the vastus lateralis (lateral thigh), ventrogluteal (hip), and deltoid.

Rotate sites to prevent lipodystrophy and injection-site nodules. Each site should rest for at least one week before reuse. A man injecting weekly can cycle through all three sites and repeat every three weeks. For self-injection, the vastus lateralis is the most accessible because it requires no torso rotation.

Subcutaneous injection of testosterone enanthate at lower volumes (0.3 to 0.5 mL) has gained traction, though it remains off-label. A 2017 retrospective study of 232 hypogonadal men found that subcutaneous testosterone cypionate (pharmacokinetically similar to enanthate) produced equivalent serum levels with fewer hematocrit elevations compared to IM injection [8]. If a patient and clinician choose subcutaneous delivery, a 27 to 30 gauge, 0.5-inch insulin syringe injected into abdominal or thigh fat is typical.

Monitoring Hematocrit and Polycythemia Risk

Erythrocytosis is the most common laboratory adverse effect of testosterone therapy. The threshold for intervention is a hematocrit above 54%, at which point venous viscosity rises enough to increase thromboembolic risk. The AUA guideline recommends checking hematocrit at 3 to 6 months, then annually [3].

A 2019 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) showed that polycythemia-related reports were the single largest safety signal for injectable testosterone products, ahead of cardiovascular and hepatic events [9]. Risk factors include baseline hematocrit above 48%, concurrent obstructive sleep apnea, smoking, and residence at altitudes above 4,000 feet.

Management options when hematocrit exceeds 54%:

• Reduce dose by 25 to 50 mg per week
• Switch from biweekly to weekly dosing (lower peaks)
• Therapeutic phlebotomy (removal of one unit, approximately 450 mL)
• Switch to a shorter-acting ester (testosterone propionate) or transdermal gel for steadier levels
• Evaluate and treat sleep apnea if untreated

Men aged 30 to 49 who exercise vigorously and maintain low body fat sometimes run hematocrit at 50 to 52% even before TRT. These patients benefit from a conservative starting dose of 75 mg weekly with early repeat labs at 4 weeks.

Managing Estradiol and Aromatization

Testosterone aromatizes to estradiol via the aromatase enzyme, which is concentrated in adipose tissue. Men with higher body fat percentages convert more testosterone to estradiol. Symptoms of elevated estradiol include nipple tenderness, water retention, mood changes, and gynecomastia.

Not every man on TRT needs estradiol management. The Endocrine Society guidelines do not recommend routine aromatase inhibitor (AI) co-prescription [1]. A practical threshold used by many clinicians is an estradiol level above 40 to 50 pg/mL with concurrent symptoms. At that point, the options are:

1. Reduce the testosterone dose (lower substrate, lower conversion)
2. Increase injection frequency (smaller boluses produce less aromatization per dose)
3. Add a low-dose AI such as anastrozole 0.25 mg twice weekly

A 2016 trial published in JAMA Internal Medicine of 790 men aged 65 and older (the T-Trials) confirmed that testosterone gel raised estradiol by a mean of 10 pg/dL alongside improvements in sexual function, vitality, and walking distance [10]. That estradiol increase was not associated with adverse events in the trial, which supports the position that mild elevations without symptoms do not require treatment.

Cardiovascular Safety Considerations for the 30-to-49 Cohort

The cardiovascular safety profile of testosterone therapy was a subject of significant regulatory scrutiny until the TRAVERSE trial settled the primary question. TRAVERSE (N = 5,246; mean age 63; median follow-up 33 months) randomized men with hypogonadism and elevated cardiovascular risk to transdermal testosterone or placebo. The primary composite endpoint of major adverse cardiovascular events (MACE) showed noninferiority for testosterone, with a hazard ratio of 0.96 (95% CI: 0.78 to 1.17) [11].

While TRAVERSE enrolled older men (ages 45 to 80), its findings are reassuring for the 30 to 49 cohort, whose baseline cardiovascular risk is substantially lower. The FDA's 2015 label update requiring a cardiovascular warning on all testosterone products remains in effect, but no randomized data support increased MACE risk in younger hypogonadal men receiving physiologic replacement doses [12].

Clinicians should still assess the 10-year ASCVD risk score at baseline, optimize lipids, and monitor blood pressure. Testosterone replacement may modestly lower HDL cholesterol by 2 to 4 mg/dL, a consistent finding across trials [7]. This effect is small and unlikely to shift risk category alone, but it warrants periodic lipid panels.

Fertility Preservation: A Priority in This Age Group

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, which reduces or eliminates spermatogenesis. For men aged 30 to 49 who want to preserve fertility, this is a non-negotiable counseling point before starting TRT.

The AUA guideline states that testosterone therapy should not be initiated in men actively trying to conceive [3]. If a patient requires androgen support but wants to maintain sperm production, alternatives include:

• Clomiphene citrate (off-label): 25 to 50 mg every other day. Stimulates endogenous testosterone production via increased LH without suppressing spermatogenesis.
• Human chorionic gonadotropin (hCG): 1,500 to 3 to 000 IU subcutaneously two to three times weekly. Maintains intratesticular testosterone and sperm counts.
• hCG co-administration with TRT: Adding hCG 500 IU three times weekly to a testosterone regimen can partially preserve spermatogenesis, though results are variable.

A 2019 retrospective cohort of 6,569 men who discontinued testosterone therapy found that 67% recovered sperm in the ejaculate within 12 months, but time to recovery ranged from 3 to 24 months and was unpredictable at the individual level [13]. Semen cryopreservation before starting TRT is the most reliable safeguard.

When to Adjust or Discontinue

Dose adjustments should follow objective data, not symptoms alone. If a patient reports persistent fatigue despite a trough testosterone of 550 ng/dL, the cause is more likely sleep, thyroid function, or depression than inadequate testosterone.

Indications for dose reduction:

• Hematocrit above 54%
• PSA velocity exceeding 1.4 ng/mL per year (prompts urology referral)
• Persistent edema or worsening sleep apnea
• Supraphysiologic trough levels (above 900 ng/dL)

Indications for discontinuation:

• Diagnosed prostate cancer or breast cancer
• Desire for fertility without willingness to co-administer hCG
• Persistent polycythemia despite dose reduction and phlebotomy
• Palpable prostate nodule or PSA above 4.0 ng/mL (pending urology evaluation)

A gradual taper is not pharmacologically required. Testosterone enanthate clears in roughly 3 weeks. Patients should be counseled that hypogonadal symptoms will return after discontinuation, typically within 3 to 6 weeks, and that recovery of endogenous production is variable, especially after prolonged use exceeding 12 months.

Practical Dosing Reference by Clinical Scenario

New diagnosis, average body composition (BMI 22 to 29): Start 100 mg IM weekly. Recheck trough testosterone and hematocrit at 6 weeks. Titrate by 25 mg increments to reach a trough of 450 to 600 ng/dL.

Elevated baseline hematocrit (50 to 52%): Start 75 mg IM weekly. Add hematocrit check at 4 weeks. If hematocrit exceeds 52% before reaching target testosterone, consider switching to transdermal.

Fertility desired within 6 to 12 months: Defer testosterone enanthate. Use clomiphene citrate 25 mg every other day or hCG monotherapy. Recheck total testosterone and semen analysis at 3 months.

Switching from gel to injectable: A man stable on 50 mg/day transdermal testosterone (producing trough levels of 400 to 500 ng/dL) typically transitions to 100 mg IM weekly. Overlap is unnecessary; begin the first injection the morning after the last gel application. Recheck labs at 6 weeks.

Obese patient (BMI above 35): Expect higher estradiol conversion. Start at 100 mg weekly, check estradiol at 6 weeks alongside testosterone and hematocrit. Prioritize weight loss counseling, as a 10% reduction in body weight can raise endogenous testosterone by 50 to 100 ng/dL [14].

The target for every scenario remains the same: a trough total testosterone of 450 to 600 ng/dL, a hematocrit below 54%, and resolution of the symptoms that prompted treatment. Dose, frequency, and route are tools to reach that target, not goals in themselves. The first repeat PSA is due at 3 to 6 months after initiation, with a referral to urology for any PSA rise exceeding 1.4 ng/mL/year or an absolute value above 4.0 ng/mL [3].